natgillin/translations-raw huggingface dataset:
The method according to any one of embodiments 45 to 46, wherein the methods comprises a step d) and a step e), which are performed at least partly simultaneously, wherein step d) comprises removing at least some of said organic acid from said liquid, wherein said acidic ion is removed through an Anion Exchange Reverse Electro-Enhanced Dialysis (AX-REED) membrane stack, said membrane stack containing 
Postupak prema zahtjevu 11, naznačen time što postupci obuhvaćaju korak d) i korak e), koji se provode barem djelomično istovremeno, pri čemu korak d) obuhvaća uklanjanje najmanje dijela navedene organske kiseline iz navedene tekućine, pri čemu navedeni kiseli ion se uklanja pomoću stoga membrana za anionsku izmjenu reverznom elektro poboljšanom dijalizom,Anion Exchange Reverse Elecitro-Enhanced Dialysis" (AX-REED), navedeni stog membrana sadrži i)
The composition according to claim 1 or the combined preparation according to claim 2, wherein said antibody or an antigen binding fragment thereof is specific for the epitope displayed by the peptide having the sequence of SEQ ID NO: 1. 
Kompozicija prema patentnom zahtjevu 1 ili kombinirani preparat prema patentnom zahtjevu 2, naznačeni time što je navedeno antitijelo ili njegov dio koji se vežu za antigen specifično/specifičan za epitop prikazan od strane peptida koji ima sekvencu SEQ ID NO: 1.
The compound for use according to any one of claims 1 to 4, wherein the administration of the compound reduces the IOP of the affected eye by at least 10% for more than 3 hours, or by at least 10-20% for more than 3 hours, or by 20% or more for more than 3 hours or by at least 10% for at least 6 hours. 
Tvar za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu primjena tvari snižava IOP zahvaćenog oka za najmanje 10% kroz više od 3 sata, ili za najmanje 10-20% kroz više od 3 sata, ili za 20% ili više kroz više od 3 sata ili za najmanje 10% kroz najmanje 6 sati.
opening the lid (5) of the pressure chamber (4); 
- < otvaranje poklopca (5) tlačne komore (4),
In one embodiment, when the heating element 5 is inserted into the heating element receiving cavity 3 the at least one of the receiving surfaces 9 may return to an original position thereby closing the heating element receiving cavity 3 and containing the heating element 5 . Fig. 4 shows a detail plan view of a routing hub 2 of the underlayment 1 in accordance with embodiments of the present disclosure. 
Podloga u skladu s patentnim zahtjevom 2, naznačena time što su najmanje dva usmjerna čvorišta (2) konfigurirana za sadržavanje najmanje jednog grijaćeg elementa putem šupljine za prihvat elementa (3) i usmjerne šupljine za prihvat elementa (3). Podloga u skladu s patentnim zahtjevom 1, naznačena time što je navedena površina za prihvat elementa (9) jedna od lučne prihvatne površine i kutne prihvatne površine.
Device according to claim 8, characterized in that it comprises a means for detecting the presence of a flexible tube (21) in the assembly for holding (26). 
Uređaj sukladno jednom od zahtjeva 1 do 8, naznačen time što sadrži sredstva za otkrivanje prisutnosti savitljive cijevi (21) u sklopu (26) za držanje.
Reacting formula III with an electrophilic bromine source, such as N-bromosuccinimide or bromine Br2, to obtain a compound of formula IV: 
€) reakcija formule M1 s elektrofilnim izvorom broma, kao što je N-bromsukcinimid ili brom Br,, da se dobije spoj formule IV:
Patent document 2: European Patent Application Publication No. 0598359 
EP 06711505.5 Datum podnošenja europske prijave patenta:
In step (a), the pluripotent cells may be cultured in the presence of vascular endothelial growth factor (VEGF) and/or bone morphogenic protein 4 (BMP-4). 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se pluripotentne stanice uzgaja u prisutnosti čimbenika rasta vaskularnog endotela (VEGF) i/ili koštanog morfogenetskog proteina 4 (BMP-4).
A pharmaceutical composition comprising trans-(±)-A9-tetrahydrocannabino in the crystalline form and a pharmaceutically-acceptable carrier for use as a medicament. 
Farmaceutski sastav koji sadrži trans-(±)-A9-tetrahidrokanabinol u kristalnom obliku i farmaceutski prihvatljiv nosač, naznačen time da se upotrebljava kao lijek.
Another embodiment is a therapeutically effective amount of a compound of the Examples for use in treating disorders selected from diabetes, obesity, Crohn's disease, systemic lupus erythematosus, glomerulonephritis, multiple sclerosis, atherosclerosis, restenosis, and organ transplantation. 
Spoj prema zahtjevu 8 ili 9, naznačen time što je za uporabu u liječenju bolesti izabrane između dijabetesa, pretilosti, Crohnove bolesti, sistemskog lupusa eritematosusa, glomerulonefritisa, multiple skleroze, ateroskleroze, restenoze i transplantacije organa.
an electrochemical cell (4) provided with a timer, suitable for producing an oxidant solution by electrolysis of an aqueous electrolytic medium during a predefined time; 
- < elektrokemijskom ćelijom (4) opremljenom mjeračem vremena, koja je prikladna za proizvodnju oksidacijske otopine elektrolizom vodenog elektrolitičkog medija tijekom prethodno određenog vremena;
a device configured to generate a band image by extracting a part of frequency components in an original image with a figure of the subject appearing therein; a device configured to calculate magnitude and a direction of gradient of a pixel value for each pixel of the band image; 
(A) uređaj za stvaranje slike na traci (12) koji ima konfiguraciju za stvaranje slike na traci (a, B, y) pomoću ekstrakcije dijela frekvencijskih komponenti u originalnoj slici (PO) s likom pojedinca koji se pojavljuje na toj slici;
for use in the treatment or prevention of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); and/or 
- namijenjeni upotrebi u liječenju ili sprječavanju akutnih egzacerbacija kronične opstruktivne plućne bolesti (AE-COPD); i/ili
A pronucleotide represented by the formula (III): or the racemates, enantiomers, diastereomers, geometric isomers, tautomers thereof, wherein 
Pronukleotid predstavljen formulom (III): (ND) ili njegovi racemati, enantiomeri, diastereomeri, geometrijski izomeri, tautomeri, u kojima
Method of producing fuel for energetics according to claim 3 characterized by that a liquid heat carrier (8), with which a space surrounding the pressure vessels (1) during heating is at least partially filled, is used for heating of the pressure vessel (1), while in the case of afterheating, the pressure vessel (1) is additionally heated with the help of at least one additional heat source functioning on a different principle of heating. 
Način za proizvodnju goriva za energetiku na temelju zahtjeva 3 1 4, naznačen time što se za zagrivanje tlačne posude (1) koristi tekući medij za prijenos topline (8), kojim se bar djelimično ispunjava prostor okružujući prilikom zagrijevanja tlačnu posudu (1), pri čemu se u slučaju dogrijavanja tlačna posuda (1) zagrijava dodatno pomoću bar jednog sljedećeg izvora topline sa funkcijom na drugom principu zagrijavanja, kao što je na primjer električni grijač.
The process according to claim 1, wherein the oxidic solid is a chrome ore residue. 
Postupak prema zahtjevu 1, naznačen time da je upotrijebljena oksidna kruta tvar ostatak kromove rude.
wherein the lower covering part comprises an edge that laterally covers a portion of the base body, wherein the edge of the lower covering part is separated into two opposing areas; and 
donji pokrovni dio (100) obuhvaća rub (102) koji lateralno pokriva bazno tijelo (41), rub donjeg pokrovnog elementa odvojen je u dva suprotna područja (103, 104);
aromatic group R12 H, alkyl group such as a methyl or ethyl group, olefinic or 
H, alkil skupina kao što je metil ili etil skupina, olefinska ili aromatska skupina Ri»
Where functional groups are lacking, they can be created by suitable chemistries that are described in standard organic chemistry texts such as Advanced Organic Chemistry, Jerry March, John Wiley &Sons (5th Ed., 2000). 
Gdje nedostaju funkcionalne grupe, mogu se napraviti odgovarajućim kemijskim reakcijama opisanim u stanardnim tekstovima iz organske kemije, kao što je Advanced Organic Chemistry, Jerry March, John Wiley & Sons (5th ed., 2000).
The method according to claim 10 where the treatment step comprises desalting the fluid immiscible with water or wherein alcohol dehydrogenase, NAD, ethylenediaminetetraacetic acid (EDTA) or another ion chelator, or catalase is added to the fluid immiscible in water either before or at the same time as the aqueous first reagent and or second reagent. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da korak obrade obuhvaća odsoljavanje tekućine koja se ne miješa s vodom ili pri čemu se alkohol dehidrogenaza, NAD, etilendiamintetraoctena kiselina (EDTA) ili neki drugi kelirajući ion ili katalaza dodaju tekućini koja se ne miješa s vodom, bilo prije ili u isto vrijeme s prvim vodenim reagensom i / ili drugim vodenim reagensom.
Also, when docking the boat, or when approaching another boat, the operator can control the boat from the sides, or from the stem or the bow. 
Također, prilikom pristajanja plovila, operater može upravljati plovilom sa strane, s krme ili s pramca.
The method of claim 1, wherein the individual does not show a symptom of hypersensitivity prior to the initiation of the treatment. 
Pripravak ili kombinacija namijenjeni upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što osoba ne pokazuje simptom preosjetljivosti prije početka liječenja,
Number of Significant Figures 
Broj međunarodne prijave:
wherein R is a (C1-C6)-alkyl group, optionally substituted aryl or optionally substituted heteroaryl; with dimethylsulfoxonium methylide to give the corresponding keto sulfoxonium glide of formula 
"COoR gdje R je (C;-C4)-alkil skupina, po izboru supstituirani aril ili po izboru supstituirani heteroaril; s dimetilsulfoksonij metilidom radi dobivanja odgovarajućeg keto sulfoksonij ilida formule
A capsule for oral administration comprising a composition according to claim 1 wherein the hydrophilic component further comprises a component selected from the group consisting of polyethyleneglycol, triethylcitrate, diethylene glycol monoethyl ether and propylene glycol. 
Kapsula za oralnu primjenu prema bilo kojem od zahtjeva 2 do 5, naznačena time, da farmaceutski sastav obuhvaća hidrofilni sastojak koji dodatno obuhvaća jedan od sastojaka koji je odabran iz skupine koju čine polietilenglikol, trietilcitrat, dietilenglikol-monoetileter i propilenglikol, a poželjno je odabran iz skupine koju čine polietilenglikol i propilenglikol.
A combination for use according to claim 3 or 4, wherein the B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija sukladno patentnim zahtjevima 3 ili 4, naznačena time, da je B2 agonist odabran iz skupine koji sadrži formoterol, salmeterol 1 OAB-149 opcionalno u obliku njihovih racemata, enantiomera, diastereomera 1 njihovih smjesa te opcionalno njihovih farmaceutski-kompatibilnih kiselinskih adicijskih soli.
The benzopyran derivative for use according to claim 1, wherein one of R2 and R3 represents a hydrogen atom; and the other of R2 and R3 represents an optionally substituted acylamino group. 
Derivat benzopirana za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da jedan od R2 i R3 predstavlja atom vodika, a drugi od R2 i R3 predstavlja po izboru supstituiranu acilamino skupinu.
The compound of claim 1 for use in the treatment of a mammal, including a human, having a disease or condition selected from the group consisting of autoimmune diseases; inflammatory diseases; autoinflammatory conditions; pain conditions; respiraratory, airway and pulmonary conditions; gastrointestinal (GI) disorders; allergic diseases; infection-based diseases; trauma and tissue injury-based conditions; fibrotic diseases; diseases driven by over-activity of IL1 pathways; ophthalmic/ocular diseases; joint, muscle and bone disorders; skin/dermatological diseases; renal diseases; genetic diseases; hematopoietic diseases; liver diseases; oral diseases; metabolic diseases, including diabetes (e.g. Type II) and complications thereof; proliferative diseases; cardiovascular conditions; vascular conditions; neuroinflammatory conditions; neurodegenerative conditions; cancer; sepsis; pulmonary inflammation and injury; or pulmonary hypertension. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju sisavca, uključujući čovjeka, koji ima bolest ili stanje kojeg se bira iz skupine koju čine autoimune bolesti; upalne bolesti; samoupalna stanja; bolna stanja; dišna, stanja dišnih puteva i plućna stanja; gastrointestinalni (GI) poremećaji; alergijske bolesti; bolesti uzrokovane infekcijama; traumatska i stanja uzrokovana ozljedom tkiva; fibrotične bolesti; bolesti uzrokovane hiperaktivnošću IL1 puteva; oftalmičke/očne bolesti; poremećaji zglobova, mišića i kostiju; kožne/dermatološke bolesti; bubrežne bolesti; genetičke bolesti; hematopoetske bolesti; bolesti jetre; bolesti usta; metaboličke bolesti, uključujući dijabetes (primjerice tip ID i njegove komplikacije; proliferativne bolesti; kardiovaskularna stanja; vaskularna stanja; neuroupalna stanja; neurodegenerativna stanja; rak; sepsa; upala i ozljeda pluća; ili plućna hipertenzija.
The use of claim 7, wherein said food or said feed commodity comprises corn meal, corn flour or corn gluten; 
Prerađena hrana ili stočna hrana prema zahtjevu 8, pri čemu spomenuta hrana ili stočna hrana obuhvaća kukuruznu krupicu, kukuruzno brašno ili kukuruzni gluten.
a second compound, the second compound being selected from an approved drug or a clinical candidate useful for the treatment of systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopic dermatitis, gout, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm; and 
Spoj u skladu s patentnim zahtjevom 1 namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je bolest ili stanje sistemni eritematozni lupus (SLE), lupozni nefritis, reumatoidni artritis, psorijaza, atopični dermatitis, giht, periodični sindrom povezan s kriopirinom (CAPS), difuzni limfom velikih B-stanica (DLBCI), kronična bolest bubrega ili akutna ozljeda bubrega, kronični opstruktivni plućni poremećaj (COPD), astma ili broncospazam.
A process for removing or reducing an impurity from solid 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-HBr or from a solution of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine-HBr, the process comprising the steps of 
Postupak uklanjanja ili reduciranja onečišćenja iz krutog 1-[2-(2,4-dimetilfenilsulfanil)fenillpiperazina-HBr ili iz otopine 1-[2-(2,4-dimetilfenilsulfaml)fenillpiperazina-HBr, postupak obuhvaća korake a) miješanje otapala koje sadržiooviše. od 65%
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, 
KG ii ili njegov stereoizomer, tautomer ili farmaceutski prihvatljiva sol, gdje, W je CRw ili N, gdje Ry je odabran iz skupine koja sadrži
A pharmaceutical aerosol solution composition according to claim 3 wherein the stabilising amount of a mineral acid is an amount of acid equivalent to 1M hydrochloric acid in the range from 0.200 to 0.227 mcg/mcl. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 4 u kojem stabilizirajuća količina mineralne kiseline jest količina kiseline ekvivalentna 1M klorovodične kiseline u rasponu od 0,200 do 0,227 ug/ul.
Method according to any of the claims 1 - 6, wherein the aqueous solution comprising a dissolved salt of Micafungin and the aqueous solution in step b) of the present method comprises Methanol. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži Metanol.
The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. 
Uporaba propranolola ili njegovih farmaceutski soli, naznačena time, da je za proizvodnju lijeka za liječenje hemangioma.
Headset apparatus according to claim 14 or 15 in which said articulation portion includes a first articulation limb (52) which is resiliently joined to a second articulation limb (53) of the articulation portion at a join therebetween such that the first articulation limb may be moved from its quiescent position relative to the second articulation limb by resilient flexure and/or torsion of either limb and/or of the join therebetween. 
Slušalice prema zahtjevu 14 ili 15, naznačene time, da zglobno vezani odsječak obuhvaća prvi zglobni krak (52) koji je elastično zglobno spojen na drugi zglobni krak (53) od zglobno vezanog odsječka na međusobnom zglobnom
The method according to claim 10, wherein the kinetic resolution with benzylamine of the mixture of epoxides (5) is conducted in a sterically hindered alcohol selected from the group consisting of sec-Butanol, tert-butanol, 2-methyl-2-butanol, isoamyl alcohol, and 2-methyl-2-pentanol, obtaining only the amino alcohol SR (8) while the epoxide SS (9) is recovered as unchanged. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se kinetičko odvajanje smjese epoksida (5) benzilaminom provodi u sterički ometanom alkoholu odabranom iz izopropanola, sec-butanola, terc-butanola, 2- metil-2-butanola, izoamil alkohola, 2-metil-2-pentanola, pri čemu se dobiva samo SR amino alkohol (8) dok se epoksid SS (9) rekuperira u nepromijenjenom obliku.
The host cell according to claims 32 and 33, which is selected from the group consisting of: HEK293, CHO, NS-0 and COS-7. 
Protutijelo ili fragment protutijela prema zahtjevu 12, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, sklerodermija i idiopatska plućna fibroza.
The communication method according to claim 15 wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated to the device by units of RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
comprising one or more of the following steps: 
o4iv Br sa spojem sljedeće strukture:
is hydrogen, fluoro, or methyl; 
R: je vodik, fluoro ili metil;
The refined extract of any one of claims 4 to 8, wherein two or more of the components of indirubin, indigo, tryptanthrin and qingdainone, are in an amount of 90%-99% (w/w) of the refined extract. 
Rafinirani ekstrakt u skladu s bilo kojim od patentnih zahtjeva 4 do 8, naznačen time što su dvoje ili više od indirubina, indiga, triptantrina i kingdainona kao komponenata, u količini od 90 % - 99 % (tež./tež.) rafiniranog ekstrakta.
Preferably, the amount of nitrogen substances in the present lights stabilising composition is limited. 
Poželjno, količina dušikovih tvari u sadašnjem pripravku za stabiliziranje na svjetlo je ograničena.
DMAP, and 60mL anhyd. DCM to dissolve the solids. 
DMAP i 60 mL bezvodnog DCM da bi se otopile krutine.
An antibody, a functional fragment thereof or an antibody mimetic which binds to BST1 for use in the treatment or prophylaxis of a disease selected from the list consisting of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer or pancreatic cancer. 
PATENTNI ZAHTJEVI 1. Antitijelo, njegov funkcionalni fragment ili mimetik antitijela koji se vezuju za BSTI1 za primjenu u liječenju ili profilaksi bolesti izabrane s liste koja se sastoji od akutne mijeloične leukemije (AML), kronične limfocitne leukemije B-stanica, karcinoma dojke, kolorektalnog karcinoma, karcinom bubrega, karcinom glave i vrata, karcinom pluća ili karcinom pankreasa.
The piezoelectric power supply converter as claimed in claim 6, wherein a shape of said substrate is of a round shape, a square shape, a rectangular shape, or other geometric forms. 
Piezoelektrični pretvornik napajanja prema zahtjevu 2, naznačen time da je oblik navedene podloge (21) okruglog oblika, kvadratnog oblika, pravokutnog oblika, ili drugih geometrijskih oblika.
represents hydrogen and R2 represents C1-6 alkyl or halo C1-6 alkyl; A is a group Ad which represents a phenyl group which may be optionally substituted by 1, 2 or 3 Ra groups; 
predstavlja vodik, a R2 predstavlja C1-6alkil ili halogen C1-6alkil; A je skupina Ad koja predstavlja fenilnu skupinu koja može biti opcijski supstituiran s 1, 2 ili 3 skupine Ra;
at least one distancing body (6) extending in the axial direction (z), 
- najmanje jedno razmakno tijelo (6), koje se pruža u smjeru osi (7),
Preferably the serine, proline or glutamate stabilized composition the invention elicits long term storage stability as characterized by: an HIC analysis at M3 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to about 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 1 wt. %. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja dovodi do stabilnosti pri dugotrajnom skladištenju, naznačena: HIC analizom u M; ili T> ili Ta gdje je količina kompozicije predstavljena pikom 2 HIC kromatograma veća od, ili jednaka 95 tež.%; 1 gdje je, ukoliko je pik 3 prisutan na HIC kromatogramu, količina kompozicije predstavljena pikom 3 manja od, ili jednaka 3 tež.%.
Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulfonate. 
U reprezentativne soli uključuju se hidrobromid, hidroklorid, sulfat, bisulfat, nitrat, acetat, oksalat, valerat, oleat, palmitat, stearat, laurat, borat, benzoat, laktat, fosfat, tosilat, citrat, maleat, fumarat, sukcinat, tartrat, naftilat, mesilat, glukoheptonat, laktiobionat, i laurilsulfonat.
Process according to any of claims 21 to 24, characterised in that following pH modification, said silicate-containing product is separated from the liquid phase and dried, thereafter comprising less than 30 %, preferably less than 50 %, and more preferably less than 66 %, by weight of said hydrophobically modified polyalkyleneimine relative to the amount of hydrophobically modified polyalkyleneimine prior to pH modification. 
Proces prema bilo kojem od zahtjeva 21 do 24, naznačen time što nakon modifikacije pH, proizvod koji sadrži silikat se odvaja od tekuće faze i suši, nakon čega sadrži manje od 30%, poželjno manje od 50%, i najpoželjnije manje od 66% težine tog hidrofobno modificiranog polialkilenimina u odnosu na količinu hidrofobno modificiranog polialkilenimina prije modifikacije pH.
Item 1. A method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising a,a,a-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, 
Postupak predviđanja terapijskog učinka kemoterapije u kojoj se upotrebljava protutumorsko sredstvo koje sadrži 0,0,a-trifluortimidin i 5-klor-6-(1-(2-iminoirolidinil)metiljuracil-hidroklorid u molarnom omjeru od 1:0.5 na pacijentu s kolorektalnim rakom, naznačen time što se postupak sastoji u koracima:
A mixture of lipochitooligosaccharides defined by the formula (I) below: wherein it comprises: 
Smjesa lipokitooligosaharida određena sljedećom formulom (I):